Abstract. Large-scale gene expression profiling is an effective strategy for understanding the progression of bladder cancer (BC). The aim of this study was to identify genes that are expressed differently in the course of BC progression and to establish new biomarkers for BC. Specimens from 21 patients with pathologically confirmed superficial (n=10) or invasive (n=11) BC and 4 normal bladder samples were studied; samples from 14 of the 21 BC samples were subjected to microarray analysis. The validity of the microarray results was verified by real-time RT-PCR. Of the 136 up-regulated genes we detected, 21 were present in all 14 BCs examined (100%), 44 in 13 (92.9%), and the other 71 in 12 BCs (85.7%). Of 69 down-regulated genes, 25 were found in all 14 BCs (100%), 22 in 13 (92.9%), and the other 22 in 12 BCs (85.7%). Functional annotation revealed that of the up-regulated genes, 36% were involved in metabolism and 14% in transcription and processing; 25% of the down-regulated genes were linked to cell adhesion/surface and 21% to cytoskeleton/cell membrane. Real-time RT-PCR confirmed the microarray results obtained for the 6 most highly up-and the 2 most highly down-regulated genes. Among the 6 most highly upregulated genes, CKS2 was the only gene with a significantly greater level of up-regulation in invasive than in superficial BC (p=0.04). To confirm this result, we subjected all 21 BC samples to real-time PCR assay for CKS2. We found a considerable difference between superficial and invasive BC (p=0.001). Interestingly, there was a considerable difference between the normal bladder and invasive BC (p=0.001) and less difference between the normal bladder and superficial BC (p=0.005). We identified several genes as promising candidates for diagnostic biomarkers of human BC and the CKS2 gene not only as a potential biomarker for diagnosing, but also for staging human BC. This is the first report demonstrating that CKS2 expression is strongly correlated with the progression of human BC.
Introduction
Bladder cancer (BC) is among the 5 most common malignancies worldwide, and the 2nd most common tumor of the genitourinary tract and the 2nd most common cause of death in patients with cancer of the urinary tract (1) (2) (3) (4) (5) (6) (7) . At diagnosis, BC with progression usually appears to be superficial (pT1); 20% of tumors with muscle invasion at the time of diagnosis tend to progress rapidly and their prognosis is unfavorable (3) (4) (5) . The ability to predict, at the first biopsy, whether a BC shift to progression is probable would facilitate the selection of appropriate treatment modalities and improve the prognosis of patients with this cancer. Due to their insufficient sensitivity and specificity, none of the biomarkers now available for the diagnosis of BC can replace cystoscopy or cytology (3, 6, 7) and patients with suspected BC continue to be subjected to painful cystoscopy.
Gene expression profiling has been used in the molecular classification of many tumor types. Molecular subtypes with potential diagnostic and prognostic implications have been identified (3, (8) (9) (10) . DNA microarrays aid in the outcome prediction for cancer patients because they facilitate the simultaneous analysis of the expression profiles of thousands of genes, making possible the identification of groups of genes with different expression profiles in tumors related to different outcomes. These gene-expression profiles assist in the selection of optimum treatment strategies by allowing therapies to be precisely adapted to different types of tumors (8) (9) (10) .
Microarray analysis have identified cancer-related genes in BC (3, 4, (11) (12) (13) (14) (15) . For example, the p33 inhibitor of the growth family 1 (p33ING1) and cathepsin E (CTSE) expression level, are correlated with the progression and prognosis of BC (11, 14) . While these studies provided useful insights into the molecular biology of BC, their sensitivity and specificity are limited and their usefulness for ONCOLOGY REPORTS 16: 521-531, 2006 521
Identification of differentially expressed genes in human bladder
cancer through genome-wide gene expression profiling predicting disease outcome remains unclear (13) (14) (15) . Using gene expression analysis and DNA microarrays, we looked for novel gene clusters related to human BC in an attempt to discover new biomarkers.
Materials and methods
Tissue samples. Tissue samples were obtained from 21 patients with BC (10 superficial, 11 invasive) who had undergone cystectomy or transurethral resection of bladder tumors at Kagoshima University Hospital, Kagoshima, Japan (Table I) . Each tumor was staged and graded according to the TNM staging system (16) and the Japanese Urological Association and the Japanese Society of Pathology (17) . Our study was approved by the Bioethics Committee of Kagoshima University; written prior informed consent was obtained from all patients for use of their samples and clinical and pathological data.
Sample preparation and total RNA extraction. Freshly harvested tissues, immediately frozen in liquid nitrogen and stored at -80˚C, were dissolved in TRIzol reagent (Invitrogen, Carlsbad, CA, USA); for total RNA extraction we followed the manufacturer's protocol. We used premium total RNA (from normal human bladder; Clontech, Palo Alto, CA, USA) as a reference for microarray analysis. RNA density was measured in an Ultrospec 3100 Pro instrument (Amersham Biosciences), RNA quality was checked in an Agilent 2100 bioanalyzer (Agilent Technologies).
Antisense RNA (aRNA) amplification. For microarray analysis we used good-quality total RNA samples from 9 patients with superficial-and 5 patients with invasive BC (samples 1-14, Table I ). aRNA was amplified from 5 μg total RNA using the amino allyl message Amp aRNA amplification kit (Ambion, Austin, TX, USA). We amplified single-strand cDNA using T7 oligos (dT), converted the product into double-stranded cDNA, purified this cDNA, and then performed amplification from double-strand cDNA templates using the manufacturer's protocol.
Dye coupling and microarray hybridization. Oligoarrays, AceGene ® human oligo chip 30K (http://bio.hitachi-sk. co.jp/acegene/index.html, Hitachi Software Engineering Co. Ltd., Yokohama, Japan) spotted with ~30,144 genes, were used for dye coupling (normal bladder -Cy3, BC -Cy5) and microarray hybridization. Pellets were formed with ethanolprecipitated aRNA (5 μg) and 5 μl CyDye (Amersham Bioscience); 5x fragmentation buffer was added after purification and following further refinement, we obtained concentrated coupled aRNA. A hybridization solution was added to the microarrays and this was followed by 18-h incubation at 50˚C.
cDNA preparation and quantitative real-time RT-PCR. Total RNA (2 μg) was mixed with 0.5 μg of oligo-dT primer and 0.4 μl of dNTPs (25 mM); a final volume of 25 μl was prepared for single-strand synthesis. Using the manufacturer's protocol, we prepared 21 cDNA samples from the same total RNA used for microarray analysis (n=14) and from 7 additional BCs. For normal bladder controls we prepared 4 cDNA samples from 3 different lots of premium total RNA (human normal bladder, Clontech) and human bladder total RNA (Chemicon International, Inc., Temecula, CA, USA). Gene-specific PCR products were assayed continuously using a 7300 Real-Time PCR system (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's protocol. Briefly, the initial PCR step was a 10 min hold at 95°C; the cycles (n=40) consisted of a 15-sec denaturation step at 95°C followed by 1-min annealing/extension at 63°C. Primers used for real-time PCR were as follows: FABP5: 5'-ttggttcagcatcaggagtg-3' (sense), 5'-cctgtccaaagtgatg atgg-3' (antisense); PABPC1: 5'-agccatgcaccctactctg-3' (sense), 5'-tctttagcttggtgggcttg-3' (antisense); CKS2: 5'-catgagccagaa ccacatattc-3' (sense), 5'-cagctcatgcacaggtatgg-3' (antisense); SF3B1: 5'-ccctagagggcctgagagtt-3' (sense), 5'-tgtgctatgagagc gtcctg-3' (antisense); DDX5: 5'-tcccaagttgcttcagttgg-3' (sense), 5'-ccttttgcccgcagagtatc-3' (antisense); EIF3S6: 5'-cttggtggcttgtcttgagg-3' (sense), 5'-atcttggcatccagtcttgc-3' (antisense); TAGLN: 5'-aagaatgatgggcactaccg-3' (sense), 5'-actgatgatctgccgaggtc-3' (antisense); TPM2: 5'-actgga caacgcactcaatg-3' (sense), 5'-gttggcaatttctgctcctc-3' (antisense); RPL37A: 5'-taccaagaaagtcgggatcg-3' (sense), 5'-tcttcatgcaggaaccacag-3' (antisense). All reactions were performed in duplicate and a negative control lacking cDNA was included. The gene encoding ribosomal protein L37a (RPL37A) served as an internal control because in our hands it showed the smallest Cy5/Cy3 fluctuation. RPL37A located on chromosome 2q35q is quite different from RPL37 located on chromosome 5p13 (Table II) . The relative mRNA expression examined was normalized to the amount of RPL37A in the same cDNA using the standard curve method provided by the manufacturer. Table I. Patient characteristics.  -------------------------------------------------No.  Age  Gender  Stage  Grade   -------------------------------------------------1  55  F  superficial  G2  2  61  M  superficial  G2  3  68  M  superficial  G2  4  68  M  superficial  G2  5  88  M  invasive  G3  6 - Table II . Frequently up-regulated genes in bladder cancer. Table II . Continued. Table II . Continued. The molecular function of the up-and down-regulated genes was classified into 13 groups as referenced in GENEONTOLOGY (http://www.geneontology.org/) and GeneCards (http://www.genecards.org/index.shtml), i.e. metabolism, transcription and processing, translation and processing, signal transduction, cell proliferation, cell-cycle regulation, cell differentiation, cell adhesion/surface-linked, cytoskeleton/cell membrane-linked, intracellular organelle, mitochondrion, other, and expressed sequence tags (ESTs) (18) .
Results

Identification of genes expressed differently in BC and normal bladder. By microarray analysis of 14 BCs we identified 136
genes that were generally up-regulated more than 1.5-fold in BC compared to normal bladder (Table II) . Among these, 21 were up-regulated in all 14 BCs (100%), 44 in 13 (92.9%), and the other 71 were up-regulated in 12 BCs (85.7%). On the contrary, 69 genes were down-regulated less than -1.5-fold (Table III) . Among these, 25 were down-regulated in all 14 BCs (100%), 22 in 13 (92.9%), and the other 22 in 12 BCs (85.7%).
Molecular function of up-and down-regulated genes in BC.
The functional annotation of the 136 up-and 69 downregulated genes is presented in Fig. 1 . Functionally, the upregulated genes were involved in metabolism (36%), transcription and processing (14%), ESTs (9%), cytoskeleton/cell membrane (7%), mitochondrion (7%), cell proliferation (6%), translation and processing (5%), signal transduction (4%), intracellular organelle (3%), and other functions (9%) (Fig.  1A) . The down-regulated genes were involved in cell adhesion/surface linked (25%), cytoskeleton/cell membrane (21%), metabolism (14%), ESTs (14%), cell differentiation (8%), cell-cycle regulation (6%), signal transduction (6%), mito-chondrion (3%), and other functions (3%) (Fig. 1B) . 
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Real-time RT-PCR verification of microarray results.
We subjected the 6 most highly up-regulated genes and the 2 most highly down-regulated genes (Tables II and III) to realtime PCR and compared our results with those obtained for normal bladder (n=4) (Fig. 2) Fig. 2B ]. Therefore, our microarray results reflect the actual mRNA levels of genes examined in our BC series.
Relationship between up-regulated genes and the BC stage.
Using the 6 most highly up-regulated genes in Table II , we compared the mRNA expression level in superficial-and invasive BCs. Real-time PCR of the 14 BCs subjected to microarray analysis demonstrated that CKS2 was the only gene with significantly higher up-regulation in invasive than in superficial BC (p=0.04) (Fig. 3) . There was no difference between superficial-and invasive BC for the other 5 examined genes (Fig. 3) . To confirm our results, we subjected all 21 BCs in this series to real-time PCR assay of CKS2 (Table I) . As shown in Fig. 4 
Discussion
We attempted to identify novel biomarkers for human BC by gene expression analysis of oligoarrays. We found that all 14 BCs subjected to microarray analysis shared 21 up-and 25 down-regulated genes; real-time RT-PCR analysis of the 6 most highly up-regulated and the 2 most highly downregulated genes confirmed our microarray results, indicating that they indeed reflect the actual mRNA levels of the genes examined in our BC series. Like others (13, 18) , we used our microarray results to classify up-and down-regulated genes by their function. We found that 36% were involved in metabolism and 14% in transcription and processing. This may implicate them in the development and progression of BC (Fig. 1) . The major function of our down-regulated genes was cell adhesion/surface-(25%) or cytoskeleton/cell membrane-related (21%), suggesting that BC cells acquire the ability to migrate via the down-regulation of these genes. Assessment of the location of the 136 up-regulated genes showed that 11 (8.1%) were on chromosome 7p, 10 (7.4%) on 8q, 8 (5.9%) on 12q, 7 each (5.1%) on 1p, 1q, and 2q, 6 each (4.4%) on 15q and 17q, 5 each (3.7%) on 2p and 20q, and 4 each (2.9%) on 5q, 7q, 14q, and 22q (Table II) . Others (19) (20) (21) have shown by comparative genomic hybridization (CGH) that the development and progression of BC is characterized by specific amplification involving chromosomes 1q, 2p, 3q, 5p, 6p, 8q, 11q, 17q, and 20q. We posit that several of the up-regulated genes in our BC series are associated with specific chromosomal amplification important in the development and progression of BC.
Among the 6 most highly up-regulated genes in our microarray analysis, FABP5, the gene with the highest level of up-regulation, carries fatty acids (FA) through the aqueous cellular environment and is involved in processes such as FA uptake, -transport, and -oxidation (22) . This gene was also up-regulated in hepatocellular carcinoma cells compared with normal hepatocytes (23) . PABPC1 is involved in translation and in the regulation of mRNA decay (24); it is significantly over-expressed in prostate cancer (25) . CKS2, which encodes a cyclin kinase subunit of Cdc28/CDC2, is involved in cell-cycle progression from G1 to S and from G2 to M; it is associated with lymphoid cell proliferation and its expression was increased in human acute lymphoblastic leukemia (26, 27) . In addition, CKS2 was expressed at significantly higher levels in colon cancer with than without liver metastasis (26) . SF3B1 is absolutely required for premRNA splicing (28) ; its relationship with human cancer has not been reported. DDX5 (p68) is a prototypic member of the so-called DEAD box family of proteins (29) and an established RNA helicase (30) ; immunohistochemistry and Western blots showed it to be consistently over-expressed in colon cancer compared with matched normal tissues (31) . EIF3S6 was first identified as a common virus insertion site in virally-induced mouse mammary tumors and preneoplastic lesions (32). Buttitta et al (33) reported that early-stage nonsmall cell lung cancer exhibited EIF3S6 mRNA levels higher than those observed in matching normal lung tissues. Ours is the first detailed investigation of these genes in human BC and our results suggest that they may be promising candidates for diagnostic BC biomarkers.
Bladder tumor antigen, the nuclear matrix protein 22, and the urinary bladder cancer antigen are clinically available diagnostic biomarkers for BC (6, 7) . However, because of their insufficient sensitivity and specificity they cannot replace cystoscopy or cytology (3, 7) and patients with suspected BC continue to require painful cystoscopy. Microarray analysis of human BC has identified new cancerrelated genes, e.g. CKS2 (4, (13) (14) (15) , NPM1 (11, 14) , PMSA (13) , and PCNA (4, 13, 15) and the results of gene profiling disclosed their association with tumor stage and progression and clinical outcomes. Although these studies have yielded useful insights into the molecular biology of human BC, they listed the genes without assessment of their value as Figure 3 . Comparison of the real-time PCR results for the 6 most highly up-regulated genes and the BC stage. Using samples from the 14 BCs subjected to microarray analysis, we found that CKS2 was the only gene that was significantly up-regulated in invasive compared to superficial BC. The relative mRNA expression examined was normalized to the amount of RPL37A. Statistical significance was determined by the Mann-Whitney U test. biomarkers. We focused on the 6 genes that were most highly up-regulated in our microarray analysis and found that CKS2 was uniquely and significantly up-regulated not only when we compared BC to normal bladder, but also when comparing invasive to superficial BC. Therefore, the CKS2 gene may be a biomarker not only for diagnosing but also for staging BC. The difference in the CKS2 expression level between invasive BC and the normal bladder was greater than between superficial BC and the normal bladder (p<0.001 vs p<0.005, Fig. 4) , suggesting that CKS2 expression may influence BC progression via cell-cycle progression. Studies are underway in our laboratory to elucidate the interactions between CKS2 and related genes in BC and to assess the role of the down-regulated genes.
In conclusion, using oligonucleotide microarrays, we found that the CKS2 gene may be a biomarker for the diagnosis and staging of BC. Ours is the first report demonstrating that CKS2 expression is strongly correlated with the progression of human BC. Our comprehensive expression profiling data of BC provide new insight into the molecular biology of BC.
